W ith the intention to reduce the number of medication errors that occur in hospitals, the Food and Drug Administration (FDA) published (February, 2004) a final rule requiring bar codes on the labels of certain drugs and biological products. 1 At a minimum, the bar code requires the drug's National Drug Code (NDC) number. With the clinical use of bar code scanning technology, health care professionals can determine that the correct drug and dose are administered to the patient.
To allow manufacturers time to exhaust inventory and allow sufficient time to make the labeling changes, a 2-year implementation period was determined for compliance. All drugs, subject to the bar code requirement, whether OTC or prescription, must have implemented the requirements by April 26, 2006. All drugs approved after that date have 60 days from their approval date to comply. However, for drugs packaged and labeled prior to April 26, 2006 without bar codes, the FDA will allow distribution until supply is depleted; 2 we should be nearing the end of non-bar coded inventory.
Because the final FDA rule requires that the bar code be included on the label, products packaged as blister cells divided by perforations (unit-of-use) must have a bar code on each unit. The code must also remain intact, so it cannot be printed across perforations. The NDC number encoded on the bar code is a 10-digit identification number divided into three segments. The first segment identifies the item by labeler (manufacturer or distributor) and is four or five characters. The second segment is the product code which is three or four characters and identifies the product by strength, dosage form, and formulation. The final segment identifies package size and is one or two characters long. The FDA has chosen not to provide guidance regarding bar code quality and format standards. There are many types of bar code symbologies; however, the three leading symbologies for unitof-use labeling are Code 39, Code 128, and Reduced Space Symbology (RSS). Each of these symbologies is allowable under the FDA rule; two-dimensional symbologies are not.
Because manufacturers and repackagers may be required at significant cost to resize unit-ofuse package labels to meet these bar coding requirements, there has been a great deal of concern for some time that unit-of-use products would be eliminated. 3 This appears to increasingly be the case. The clinical application of bar coding technology yields a significant reduction in medication errors with modest outlay. It is unfortunate that some manufacturers have chosen to transfer the costs of relabeling and bar coding to the pharmacy.
At the time of publication, I could not locate a comprehensive resource listing those unit-of-use products that are bar coded or one listing unit dose product line deletions. If this information would be helpful to you, or if you are aware of a resource for these data, please contact me at Dennis.Cada@ WoltersKluwer.com.
